- Home
- BL vs CMPS Comparison
BL vs CMPS Comparison
Compare BL & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BL | CMPS |
|---|---|---|
| Founded | 2001 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BL | CMPS |
|---|---|---|
| Price | $34.58 | $11.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $38.10 | $23.75 |
| AVG Volume (30 Days) | 862.0K | ★ 2.2M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $177,031,000.00 | N/A |
| Revenue This Year | $9.48 | N/A |
| Revenue Next Year | $10.41 | N/A |
| P/E Ratio | $85.90 | ★ N/A |
| Revenue Growth | ★ 43.78 | N/A |
| 52 Week Low | $24.70 | $4.88 |
| 52 Week High | $59.57 | $15.87 |
Technical Indicators
Market Signals| Indicator | BL | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 74.03 | 40.13 |
| Support Level | $25.57 | $10.68 |
| Resistance Level | $38.35 | $14.74 |
| Average True Range (ATR) | 1.16 | 0.57 |
| MACD | 0.68 | 0.05 |
| Stochastic Oscillator | 99.49 | 31.79 |
Price Performance
Historical ComparisonAbout BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.